BRIEF-Heat Biologics presents immune data on bladder cancer drug
Feb 17 Heat Biologics Inc-
* Researchers reported that hs-410, in combination with bcg, continues to be generally well-tolerated
* Researchers reported hs-410 activates cd8+ t cells and these immune responders appear to have lower recurrence rate than non-immune responders
* Patients were evaluated based on their levels of tumor infiltrating lymphocytes (til) at start of treatment in phase 2 trial
* In placebo arm, patients with low til levels at baseline had higher incidence of disease recurrence than patients with high til levels at baseline
* In vaccine-treated group, recurrence levels were essentially same between high and low til subgroups, at 25% and 29%, respectively
* Continues to monitor all patients enrolled in study for a 2-year duration Source text for Eikon: Further company coverage:
|
Thread abonnieren
ETF-Sparplan